Beta Bionics vs Infusystem Holdings
Infusystem Holdings is the larger business, with $143m of revenue in fiscal 2025 against $100m for Beta Bionics (1.4 times as much). Beta Bionics grew faster (53.9% against 6.4%). Infusystem Holdings kept more of each dollar of sales as profit: a net margin of 4.6% against -73.0%. Beta Bionics carries less debt relative to equity (0.0% against 34.9%).
| Latest fiscal year | Beta BionicsBBNX, 2025 | Infusystem HoldingsINFU, 2025 |
|---|---|---|
| Revenue | $100m | $143m |
| Revenue growth | 53.9% | 6.4% |
| Net income | −$73.2m | $6.6m |
| Operating margin | -71.5% | 8.3% |
| Net margin | -73.0% | 4.6% |
| Return on equity | — | 11.5% |
| Free cash flow | −$56.2m | $23.8m |
| Cash | $31.6m | $3.2m |
| Total debt | $0 | $20.0m |
| Debt to equity | 0.0% | 34.9% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $9.9m |
| Employees | 420 | 473 |
| Market value | $817m | $255m |
| Price vs our value range | — | Within our value range |
| Moat score | — | 64 (Moderate) |
| Insider trades, 12 months | 0 buys, 52 sales | 5 buys, 0 sales |